Use of Prothrombin Complex Concentrate in Patients during Heart Transplantation after Implantation of a Left Ventricular Mechanical Support System
https://doi.org/10.15360/1813-9779-2012-6-58
Abstract
Heart transplantation in patients after implantation of mechanical cardiac support devices entails an extremely high risk for perioperative bleeding. Recombinant activated coagulation factor VII is presently used to reduce the volume of bleeding in this patient group. There are parallel data on its administration-induced thromboembolic events in the literature. This paper describes a case of using a prothrombin complex concentrate in a patient during explantation of a left ventricular bypass system and subsequent orthotopic heart transplantation in the presence of significant hypocoagulation. At the end of a surgery, 1200 IU of the agent was used at a remaining bleeding rate of more than 1000 ml/hour. Within the first 24 hours after surgery, the rate of discharge drainage was less than 100 ml/hour. A control plain chest X-ray study revealed massive left-sided hydrothorax on day 2 postsurgery. The left pleural cavity was revised under thoracoscopic guidance and 1000 ml of blood clots were evacuated. Although the administration of prothrombin complex concentrate did not guard against re-intervention, its use seems a promising strategy in life-threatening bleedings in patients after explantation of mechanical cardiac support devices. Further multicenter investigations are required to determine the efficacy and safety of prothrom-bin complex concentration in cardiac surgery. Key words: Recombinant activated coagulation factor VII, prothrombin complex concentration, mechanical cardiac support device, orthotopic heart transplantation.
About the Authors
V. V. LomivorotovV. A. Shmyrev
M. N. Deryagin
S. M. Efremov
I. A. Kornilov
A. M. Chernyavsky
References
1. McCarthy P.M., Sabik J.F.Semin. Thorac. Cardiovasc. Surg.
2. Masud F., Bostan F., Chi E., Pass S.E., Samir H., Stuebing K., Liebl M.G.Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes.J. Cardiothorac. Vasc. Anesth.2009; 23 (1): 28—33.
3. O’Connell K.A., Wood J J., Wise R.P., Lozier J.N., Braun M.M.Thromboembolic adverse events after use of recombinant human coagulation factorVIIa.JAMA.2006; 295 (3): 293—298.
4. Шумаков Д.В., Шемакин С.Ю., Козлов ИЛ., Попцов В.Н., Кормер А.Я., Романов О.В., Нехрест А.Н., Халилулин Т., Пестрецова Т.В., Шмерко Н.П., Шумаков В.И.Первый в Российской федерации опыт применения в клинике имплантируемого осевого насоса INCOR для левожелудочкового обхода.Вестн. трансплантологии и искусственных органов.2007; 9 (1): 19—27.
5. Didisheim P., Olsen D.B., Farrar D.J., Portner P.M., Griffith B.P., Pennington D.G., Joist J.H., Schoen F.J., Gristina A.G., Anderson J.M.Infection and thromboembolism with implantable cardiovascular devices.ASAIO Trans.1989; 35 (1): 54—70.
6. Dembitsky W.P., Tector A.J., Park S., Moskowitz A.J., Gelijns A.C., Ronan N.S., Piccione WJr., Holman W.L., Furukawa S., Weinberg A.D., Heatley G., Poirier V.L., Damme L., Long J.W.Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial.Ann. Thorac. Surg.2004; 78 (6): 2123—2129.
7. Koch C.G., Li L., Duncan A.I., Mihaljevic T., Cosgrove D.M., Loop F.D., Starr N.J., Blackstone E.H.Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting.Crit. Care Med.2006; 34 (6): 1608—1616.
8. МарутянЗ.Г., НикифоровЮ.В., КазанцевА.Б., Тер-ГригорянАА.Современные кровесберегающие технологии при реконструкции таза.Общаяреаниматология.2010; 6 (4): 66—69.
9. Baglin T.P., Keeling D.M., Watson H.G.Guidelines on oral anticoagula-tion (warfarin): third edition — 2005 update.Br. J. Haematol.2006; 132 (3): 277—285.
10. DiDomenico R.J., MassadM.G., KpodonuJ., Navarro R.A., Geha A.S.Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass.Chest.2005; 127 (5): 1828—1835.
11. Рипп Е.Г., Шписман М. Н.Значение экспресс-диагностики дисфункции системы гемостаза у больных с травмой и острой кровопоте-рей.Общаяреаниматология.2010; 6 (3): 57—60.
12. Gandhi M.J., Pierce R.A., Zhang L., Moon M.R., Despotis G.J., Moazami N.Use of recombinant factor VII for severe coagulopathy post ventricular assist device of orthotopic heart transplantation.J. Cardiothorac. Surg.2007; 2: 32.
13. Ponschab M., Landoni G., Biondi-Zoccai G., Bignami E., Frati E., Nicolotti D., Monaco F., Pappalardo F., Zangrillo A.Recombinant activated factor VIII increases stroke in cardiac surgery: a meta-analysis.J. Cardothorac. Vasc. Anesth.2011; 25 (5): 804—810.
14. Bruce D., Nokes T.J.Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital.Crit. Care.2008; 12 (4): R105.
15. Whitlock R., Crowther M.A., Ng H.J.Bleeding in cardiac surgery: its prevention and treatment — an evidence-based review.Crit. Care Clin.2005; 21 (3): 589—610.
16. Pabinger I., Brenner B., Kalina U., Knaub S., Nagy A., Ostermann H.Prothrombin complex concentrate (Beriplex P/N) for emergency anti-coagulation reversal: a prospective multinational clinical trial.J. Thromb Haemost.2008; 6 (4): 622—631.
Review
For citations:
Lomivorotov V.V., Shmyrev V.A., Deryagin M.N., Efremov S.M., Kornilov I.A., Chernyavsky A.M. Use of Prothrombin Complex Concentrate in Patients during Heart Transplantation after Implantation of a Left Ventricular Mechanical Support System. General Reanimatology. 2012;8(6):58. (In Russ.) https://doi.org/10.15360/1813-9779-2012-6-58
Views:
1534
Email this article 